Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAXUS Atom refers to a family of paclitaxel-eluting coronary stent systems developed by Boston Scientific for the treatment of coronary artery disease in small vessels (diameters as small as 2.25 mm). The product line includes the first-generation TAXUS Express2 Atom and the second-generation TAXUS Liberté Atom. These are drug-device combination products consisting of a metallic stent platform coated with a polymer that provides controlled release of paclitaxel. Paclitaxel acts as an antirestenotic agent by stabilizing microtubules, which inhibits smooth muscle cell migration and proliferation, thereby preventing neointimal hyperplasia and restenosis after percutaneous coronary intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TAXUS Atom.